

Overview of Diabetic Retinopathy

| Resource | Address |
|--|---|
| Diabetic macular edema: pathogenesis and treatment (Bhagat N. et al, <i>Surv Ophthalmol.</i> 2009) | https://www.ncbi.nlm.nih.gov/pubmed/19171208 |
| Diabetic Retinopathy: A Position Statement by the American Diabetes Association (Solomon SD, et al. <i>Diabetes Care.</i> 2017) | http://care.diabetesjournals.org/content/40/3/412 |
| Diabetic Retinopathy: Pathophysiology and Treatments (Wang W, Lo AC. <i>Int J Mol Sci.</i> 2018) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032159/ |
| Facts About Diabetic Eye Disease (NIH) | https://nei.nih.gov/health/diabetic/retinopathy |
| ICO Guidelines for Diabetic Eye Care (International Council of Ophthalmology, updated 2017) | http://www.icoph.org/downloads/ICOGuidelinesforDiabeticEyeCare.pdf |
| Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy (Adamis AP, et al. <i>Am J Ophthalmol.</i> 1994) | https://www.ncbi.nlm.nih.gov/pubmed/?term=Am+J+Ophthalmol.+1994%3B+118%3A445- |
| Inflammation in Diabetic Retinopathy (Tang J, Kern TS. <i>Prog Retin Eye Res.</i> 2012) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433044/ |
| Oxidative Stress and Diabetic Retinopathy (Kowluru RA and Chan P-S, <i>Exp Diabetes Res.</i> 2007) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1880867/ |
| Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999-2002 and 2005-2008 (Ko F, et al. <i>JAMA.</i> 2012) | https://www.ncbi.nlm.nih.gov/pubmed/23232894 |
| Pathophysiology of Diabetic Macular Edema (Singh A, Stewart JM. <i>Int Ophthalmol Clin.</i> 2009) | https://journals.lww.com/international-ophthalmology/Citation/2009/04920/Pathophysiology_of_Diabetic_Macular_Edema.3.aspx |
| Pathophysiology of Diabetic Retinopathy: The Old and the New (Kusuhara S et al, <i>Diabetes Metab J,</i> 2018) | https://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-42-364.pdf |
| The Diabetic Retinopathy Barometer Study: Global perspectives on access to and experiences of diabetic retinopathy screening and treatment (Cavan D et al, <i>Diabetes Res Clin Pract,</i> 2018) | https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(17)30437-0/fulltext |

| | |
|--|---|
| The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema (Relhan N and Flynn HW JR, <i>Curr Opin Ophthalmol</i> , 2017) | https://www.ncbi.nlm.nih.gov/pubmed/?term=Current+Opinion+in+Ophthalmology%3A+May+2017+-+Volume+28+-+Issue+3+-+p+205-212 |
| The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus (The Diabetes Control and Complications Trial Research Group, <i>N Engl J Med</i> , 1993) | https://www.nejm.org/doi/full/10.1056/nejm199309303291401?cookieSet=1 |
| The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic Macular Edema (Klein R et al, <i>Ophthalmology</i> , 1984) | https://www.aaojournal.org/article/S0161-6420(84)34102-1/pdf |
| Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives (Caldwell RB et al, <i>Diabetes Metab Res Rev</i> , 2003) | https://www.ncbi.nlm.nih.gov/pubmed/?term=Diabetes+Metab+Res+Rev+.+2003%3B19%3A442-455 |
| Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders (Aiello LP et al, <i>N Engl J Med</i> , 1994) | https://www.nejm.org/doi/10.1056/NEJM199412013312203?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov |

DR/DME Therapy-Related Studies

| Resource | Address |
|---|---|
| Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema (DRCRN, et al. <i>N Engl J Med</i> . 2015) | https://www.ncbi.nlm.nih.gov/pubmed/25692915?dopt=Abstract |
| Association Between the Severity of Diabetic Retinopathy and Falls in an Asian Population With Diabetes: The Singapore Epidemiology of Eye Diseases Study (Gupta P, et al. <i>JAMA Ophthalmol</i> . 2017) | https://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+Ophthalmol.+2017%3B135(12)%3A1410-1416 |
| A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE) (RIDE) NCT00473382 | https://clinicaltrials.gov/ct2/show/NCT00473382?term=NCT00473382&rank=1 |

| | |
|--|--|
| <p>A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE) (RISE) NCT00473330</p> | <p>https://clinicaltrials.gov/ct2/show/NCT00473330</p> |
| <p>A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study (RESTORE) NCT00687804</p> | <p>https://clinicaltrials.gov/ct2/show/NCT00687804?term=Restore+macular+edema&rank=1</p> |
| <p>Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (Protocol T) NCT01627249</p> | <p>https://clinicaltrials.gov/ct2/show/NCT01627249</p> |
| <p>ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics (Li AL, et al. <i>Retina</i>. 2016)</p> | <p>https://www.ncbi.nlm.nih.gov/pubmed/?term=Retina.+2016%3B36(7)%3A1349-56</p> |
| <p>Evidence-Based Guidelines for Management of Diabetic Macular Edema (Bakri SJ, et al. <i>J Vitreoretin Dis</i>. 2019).</p> | <p>https://journals.sagepub.com/doi/full/10.1177/2474126419834711</p> |
| <p>Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab (Bressler SB, et al, <i>Arch Ophthalmol</i>. 2012)</p> | <p>https://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Ophthalmol+2012%3B+130+(9)%3A+1153-1161</p> |
| <p>Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial (Gross JG et al, <i>JAMA Ophthalmol</i>, 2018)</p> | <p>https://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+Ophthalmol.+2018%3B136(10)%3A1138-1148</p> |
| <p>Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies (Heier JS, et al. <i>Ophthalmology</i>. 2016)</p> | <p>https://www.sciencedirect.com/science/article/pii/S0161642016307382</p> |
| <p>Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser</p> | <p>https://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+Ophthalmol.%C2%A02017%3B135(2)%3A107-114</p> |

| | |
|--|---|
| Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials (Wykoff CC, et al, <i>JAMA Ophthalmol.</i> 2017) | |
| Intravitreal Aflibercept Injection in Vision Impairment Due to DME (VIVID-DME) NCT01331681 | https://clinicaltrials.gov/ct2/show/NCT01331681 |
| Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial (Gross JG et al, <i>JAMA Ophthalmol.</i> 2018) | https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2688792 |
| Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial NCT02299336 | https://clinicaltrials.gov/ct2/show/NCT02299336?term=VISTA&rank=9 |
| Long-term effects of ranibizumab on diabetic retinopathy severity and progression (Ip MS, et al. <i>Arch Ophthalmol.</i> 2012) | https://www.ncbi.nlm.nih.gov/pubmed/?term=Arch+Ophthalmol.+2012%3B130(9)%3A1145-1152. |
| Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE (Brown DM, et al. <i>Ophthalmology.</i> 2013) | https://www.ncbi.nlm.nih.gov/pubmed/23706949 |
| Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study (Wykoff CC, et al. <i>Br J Ophthalmol.</i> 2018) | https://www.ncbi.nlm.nih.gov/pubmed/?term=2Br+J+Ophthalmol.+2018%3B102(5)%3A631-636 |
| Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections (Obeid A et al. <i>Ophthalmology.</i> 2018) | https://www.ncbi.nlm.nih.gov/pubmed/?term=Ophthalmology.+2018+Sep%3B125(9)%3A1386-1392 |
| Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema (Campochiaro PA, et al. <i>Ophthalmol.</i> 2014) | https://www.ncbi.nlm.nih.gov/pubmed/?term=Ophthalmology.+2014%3B121(9)%3A1783-9 |
| Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term | https://www.ncbi.nlm.nih.gov/pubmed/?term=Ophthalmology.+2015+Dec%3B122(12)%3A2504-13.e1 |

| | |
|--|---|
| Outcomes of the Phase III RIDE and RISE Trials (Boyer DS, et al. <i>Ophthalmology</i> . 2015) | |
| Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol S) NCT01489189 | https://clinicaltrials.gov/ct2/show/NCT01489189?term=Protocol+S&rank=1 |
| Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy (Wykoff CC, et al. <i>Ophthalmology Retina</i> . 2018) | https://ophthalmologyretina.org/action/showFullTextImages?pii=S2468-6530%2818%2930047-2 |
| Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy (Sun JK, et al. <i>Ophthalmology</i> . 2019) | https://www.ncbi.nlm.nih.gov/pubmed/30096354 |
| Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study (Mazhar K, et al, <i>Ophthalmology</i> . 2011) | https://www.ncbi.nlm.nih.gov/pubmed/?term=Ophthalmology.+2011+Apr%3B118(4)%3A649-55 |
| Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema (VISTA DME) NCT01363440 | https://clinicaltrials.gov/ct2/show/NCT01363440 |
| Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA) NCT02718326 | https://clinicaltrials.gov/ct2/show/NCT02718326?term=PANORAMA&rank=5 |
| The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good (Ho AC, et al. <i>JAMA Ophthalmol</i> , 2017) | https://www.ncbi.nlm.nih.gov/pubmed/?term=Ophthalmology.+2017%3B+135(3)%3A+268-273 |
| Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE | https://www.ncbi.nlm.nih.gov/pubmed/26327116?dopt=Abstract |

| | |
|---|---|
| extension study (Mitchell P, et al, <i>Curr Med Res Opin.</i> 2015) | |
| Treatment for CI-DME in Eyes With Very Good VA Study (Protocol V) NCT01909791 | https://clinicaltrials.gov/ct2/show/NCT01909791?term=DRCR+V&rank=1 |
| Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE (Bressler NM, et al. <i>Ophthalmology</i> , 2014). | https://www.ncbi.nlm.nih.gov/pubmed/25148789?dopt=Abstract |
| Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States (Willis JR, et al. <i>JAMA Ophthalmol</i> , 2017) | https://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+Ophthalmol.+2017%3B135(9)%3A926-932 |

Interdisciplinary Care

| Resource | Address |
|--|---|
| Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration (Strain WD, et al, <i>Diabetes Res Clin Pract.</i> 2017) | https://www.sciencedirect.com/science/article/pii/S0168822716315248 |
| Improving Diabetic Retinopathy Screening is a Complex Challenge (Zeimer DC, et al. <i>ADA 2016 Congress</i> , Poster 617-P) | https://ada.scientificposters.com/epsAbstractADA.cfm?id=1 |
| Interpersonal continuity of care and type two diabetes (Lustman A, et al. <i>Primary Care Diabetes.</i> 2016) | https://www.sciencedirect.com/science/article/pii/S1751991815001266 |

Patient Resources

| Resource | Address |
|---|---|
| Diabetic Macular Edema (DME) – Prevent Blindness | https://www.preventblindness.org/diabetic-macular-edema-dme |
| Diabetic Retinopathy (The Discovery Eye Foundation) | https://discoveryeye.org/eye-conditions/diabetic-retinopathy/ |

| | |
|--|---|
| Diabetic Retinopathy (The Foundation Fighting Blindness) | https://ffb.ca/learn/diabetic-retinopathy/ |
| Diabetic Retinopathy: What is diabetic eye disease? (International Macular and Retinal Foundation) | https://internationalmacularandretinalfoundation.org/what-is-diabetic-retinopathy/ |
| Facts About Diabetic Eye Disease (NIH) | https://nei.nih.gov/health/diabetic/retinopathy |